metformin has been researched along with Coronary Restenosis in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Logistic regression showed that d, L, different therapeutic agents, and dosage groups were independent risk factors of ISR." | 5.72 | Treatment effect of metformin combined with atorvastatin in reducing in-stent restenosis after percutaneous coronary intervention in coronary artery disease patients with type 2 diabetic patients. ( Chen, M; Li, M; Liu, S; Ma, F; Su, B; Wang, C; Yuan, L; Zhang, S; Zhang, Y; Zheng, Q, 2022) |
| "Insulin resistance is central to the pathogenesis of type 2 diabetes and may contribute to atherogenesis, either directly or through associated risk factors." | 2.42 | Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. ( Evans, M; Rees, A; Roberts, AW; Thomas, A, 2003) |
| " Logistic regression showed that d, L, different therapeutic agents, and dosage groups were independent risk factors of ISR." | 1.72 | Treatment effect of metformin combined with atorvastatin in reducing in-stent restenosis after percutaneous coronary intervention in coronary artery disease patients with type 2 diabetic patients. ( Chen, M; Li, M; Liu, S; Ma, F; Su, B; Wang, C; Yuan, L; Zhang, S; Zhang, Y; Zheng, Q, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Ma, F | 1 |
| Su, B | 1 |
| Wang, C | 1 |
| Zheng, Q | 1 |
| Zhang, Y | 1 |
| Li, M | 1 |
| Liu, S | 1 |
| Zhang, S | 1 |
| Yuan, L | 1 |
| Roberts, AW | 1 |
| Thomas, A | 1 |
| Rees, A | 1 |
| Evans, M | 1 |
| Kao, J | 1 |
| Tobis, J | 1 |
| McClelland, RL | 1 |
| Heaton, MR | 1 |
| Davis, BR | 1 |
| Holmes, DR | 1 |
| Currier, JW | 1 |
1 review available for metformin and Coronary Restenosis
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Resten | 2003 |
2 other studies available for metformin and Coronary Restenosis
| Article | Year |
|---|---|
Treatment effect of metformin combined with atorvastatin in reducing in-stent restenosis after percutaneous coronary intervention in coronary artery disease patients with type 2 diabetic patients.
Topics: Atorvastatin; Blood Glucose; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Dia | 2022 |
Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention.
Topics: Angioplasty, Balloon, Coronary; Case-Control Studies; Coronary Restenosis; Databases, Factual; Diabe | 2004 |